Minireviews
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. May 16, 2021; 9(14): 3238-3251
Published online May 16, 2021. doi: 10.12998/wjcc.v9.i14.3238
Prediction models for development of hepatocellular carcinoma in chronic hepatitis B patients
Jiang Guo, Xue-Song Gao
Jiang Guo, Department of Interventional Oncology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
Xue-Song Gao, Department of General Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
Author contributions: Guo J conducted the literature search and wrote the first version of the manuscript; Gao XS conceived of the manuscript, designed the review, and revised the final version of the manuscript.
Supported by National Science and Technology Major Project of China, No. 2018ZX10715-005-003-002; and Health Development and Scientific Research in the Capital, No. 2018-1-2181.
Conflict-of-interest statement: There is no conflict of interest to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Xue-Song Gao, MD, PhD, Chief Physician, Department of General Medicine, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshundong Street, Chaoyang District, Beijing 100015, China. gaoxuesong@ccmu.edu.cn
Received: January 18, 2021
Peer-review started: January 18, 2021
First decision: February 9, 2021
Revised: February 11, 2021
Accepted: March 17, 2021
Article in press: March 17, 2021
Published online: May 16, 2021
Processing time: 100 Days and 20.7 Hours
Core Tip

Core Tip: Risk scores are useful in estimating hepatocellular carcinoma (HCC) risk in chronic hepatitis B (CHB) patients. While antiviral therapy does not eliminate the risk of hepatitis B virus (HBV)-related HCC, it modifies the natural disease course to reduce the HCC risk. CU-HCC (Chinese University-HCC), GAG-HCC (guide with age, gender, HBV DNA, core promoter mutations and cirrhosis), and REACH-B (risk estimation for HCC in CHB) scores derived from Asian CHB patients were also accurate in treated patients. The PAGE-B (platelet, age, and gender-hepatitis B) score has persistently high predictability for treated Caucasian and Asian patients with different HCC risk profiles.